收稿日期: 2024-01-04
网络出版日期: 2024-05-15
基金资助
江苏省卫健委面上项目(M2021093)
Safety and efficacy of radiotherapy and PD⁃1/PD⁃L1 inhibitor + TKI for MSS/pMMR colorectal cancer with liver metastases
Received date: 2024-01-04
Online published: 2024-05-15
目的 观察放疗联合程序死亡受体-1（PD-1）抑制剂及酪氨酸激酶抑制剂（TKI），治疗微卫星稳定（MSS）型或错配修复正常（pMMR）型结直肠癌肝转移（CCLM）的疗效及安全性。 方法 回顾性分析江苏省肿瘤医院2021年4月至2023年8月收治的25例MSS型CCLM患者的病历资料。分为观察组（n = 12）和对照组（n = 13）。观察组给予放疗联合PD-1抑制剂及TKI治疗，对照组给予TKI单药治疗。比较两组患者的基线资料、治疗效果、无进展生存期以及治疗相关不良反应。 结果 两组患者的基线资料差异无统计学意义（P > 0.05），观察组的疾病控制率高于对照组（P < 0.05），对照组患者的无进展生存期长于观察组，但差异无统计学意义（P > 0.05），两组患者的治疗相关不良事件发生率差异无统计学意义（P > 0.05）。 结论 放疗联合PD-1抑制剂及TKI药物的治疗方案与单用TKI对比，提高了MSS型结直肠癌肝转移患者的临床疗效，且未增加不良反应发生率，是一种值得进一步验证的治疗方案。
丁宇轩 , 郭沥泞 , 沈佳怡 , 王丽君 . 放疗联合PD-1抑制剂及酪氨酸激酶抑制剂治疗MSS型结直肠癌肝转移疗效及安全性[J]. 实用医学杂志, 2024 , 40(9) : 1293 -1297 . DOI: 10.3969/j.issn.1006-5725.2024.09.019
Objective To observe the efficacy and safety of radiotherapy combined with programmed death receptor?1 （PD?1） inhibitors and tyrosine kinase inhibitors （TKIs） for the treatment of microsatellite?stabilized （MSS）?type or mismatch?matched repair?normal （pMMR）?type colorectal cancer with liver metastases （CCLM）. Methods Case data of 25 patients with MSS?type CCLM admitted to Jiangsu Provincial Cancer Hospital from April 2021 to August 2023 were retrospectively analyzed. They were divided into observation group （n = 12） and control group （n = 13）. The observation group was given radiotherapy combined with PD?1 inhibitor and TKI treatment， and the control group was given TKI monotherapy. The baseline data， treatment effect， progression?free survival， and treatment?related adverse reactions of patients in the two groups were compared. Results The difference in baseline data between the two groups was not statistically significant （P > 0.05）， the disease control rate （DCR） of the observation group was higher than that of the control group （P < 0.05）， the progression?free survival （PFS） of the patients in the observation group was longer than that of the control group， but the difference was not statistically significant （P > 0.05）， and the difference in the incidence of treatment?related adverse events （TRAE） between the two groups was not statistically significant （P > 0.05）. Conclusion The treatment regimen of radiotherapy combined with PD?1 inhibitors and TKI drugs improved clinical efficacy and did not increase the incidence of adverse events when compared with TKI alone， which is a treatment regimen worthy of further validation.
| 1 | SUNG H， FERLAY J， SIEGEL R L， et al. Global Cancer Statistics 2020： GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries［J］. CA Cancer J Clin， 2021， 71（3）： 209-249. doi:10.3322/caac.21660 |
| 2 | 周雄， 胡明， 李子帅， 等. 2020年全球及中国结直肠癌流行状况分析［J］. 海军军医大学学报， 2022， 43（12）： 1356-1364. |
| 3 | MA Z H， WANG Y P， ZHENG W H， et al. Prognostic factors and therapeutic effects of different treatment modalities for colorectal cancer liver metastases［J］. World J Gastrointest Oncol， 2020， 12（10）： 1177-1194. doi:10.4251/wjgo.v12.i10.1177 |
| 4 | ELFRINK A K E， NIEUWENHUIZEN S， VAN DEN TOL M P， et al. Hospital variation in combined liver resection and thermal ablation for colorectal liver metastases and impact on short-term postoperative outcomes： a nationwide population-based study［J］. HPB （Oxford）， 2021， 23（6）： 827-839. |
| 5 | ZHANG Z， LIU X， CHEN D， et al. Radiotherapy combined with immunotherapy： the dawn of cancer treatment［J］. Signal Transduct Target Ther， 2022， 7（1）： 258. doi:10.1038/s41392-022-01102-y |
| 6 | LIPPERT T P， GREENBERG R A. The abscopal effect： a sense of DNA damage is in the air［J］. J Clin Invest， 2021， 131（9）： e148274. doi:10.1172/jci148274 |
| 7 | YI M， JIAO D， QIN S， et al. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment［J］. Mol Cancer， 2019， 18（1）： 60. doi:10.1186/s12943-019-0974-6 |
| 8 | EISENHAUER E A， THERASSE P， BOGAERTS J， et al. New response evaluation criteria in solid tumours： revised RECIST guideline （version 1.1）［J］. Eur J Cancer， 2009， 45（2）： 228-247. doi:10.1016/j.ejca.2008.10.026 |
| 9 | CHANDRA R， KARALIS J D， LIU C， et al. The Colorectal Cancer Tumor Microenvironment and Its Impact on Liver and Lung Metastasis［J］. Cancers （Basel）， 2021， 13（24）： 6206. doi:10.3390/cancers13246206 |
| 10 | STEWART C L， WARNER S， ITO K， et al. Cytoreduction for colorectal metastases： liver， lung， peritoneum， nodeslymph， bone， brain. When does it palliate， prolong survival， and potentially cure？［J/OL］. Curr Probl Surg， 2018， 55（9）： 330-379. doi:10.1067/j.cpsurg.2018.08.004 |
| 11 | LI J， QIN S， XU R H， et al. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer： The FRESCO Randomized Clinical Trial［J］. JAMA， 2018， 319（24）： 2486-2496. doi:10.1001/jama.2018.7855 |
| 12 | LI J， QIN S， XU R， et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer （CONCUR）： a randomised， double-blind， placebo-controlled， phase 3 trial［J］. Lancet Oncol， 2015， 16（6）： 619-629. doi:10.1016/s1470-2045(15)70156-7 |
| 13 | DOLESCHEL D， HOFF S， KOLETNIK S， et al. Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth［J］. J Exp Clin Cancer Res， 2021， 40（1）： 288. doi:10.1186/s13046-021-02043-0 |
| 14 | SONG Y， FU Y， XIE Q， et al. Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors： A Promising Strategy for Cancer Treatment［J］. Front Immunol， 2020， 11： 1956. doi:10.3389/fimmu.2020.01956 |
| 15 | HUANG Y， STYLIANOPOULOS T， DUDA D G， et al. Benefits of vascular normalization are dose and time dependent--letter［J］. Cancer Res， 2013， 73（23）： 7144-7146. doi:10.1158/0008-5472.can-13-1989 |
| 16 | ZHANG W， ZHANG Z， LOU S， et al. Efficacy， safety and predictors of combined fruquintinib with programmed death-1 inhibitors for advanced microsatellite-stable colorectal cancer： A retrospective study［J］. Front Oncol， 2022， 12： 929342. doi:10.3389/fonc.2022.929342 |
| 17 | FUKUOKA S， HARA H， TAKAHASHI N， et al. Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer： An Open-Label， Dose-Escalation， and Dose-Expansion Phase Ib Trial （REGONIVO， EPOC1603）［J］. J Clin Oncol， 2020， 38（18）： 2053-2061. doi:10.1200/jco.19.03296 |
| 18 | MCLAUGHLIN M， PATIN E C， PEDERSEN M， et al. Inflammatory microenvironment remodelling by tumour cells after radiotherapy［J］. Nat Rev Cancer， 2020， 20（4）： 203-217. doi:10.1038/s41568-020-0246-1 |
| 19 | RODRIGUEZ-RUIZ M E， RODRIGUEZ I， GARASA S， et al. Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming［J］. Cancer Res， 2016， 76（20）： 5994-6005. doi:10.1158/0008-5472.can-16-0549 |
| 20 | GRIMALDI A M， SIMEONE E， GIANNARELLI D， et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy［J］. Oncoimmunology， 2014， 3： e28780. doi:10.4161/onci.28780 |
| 21 | CAMPHAUSEN K， MOSES M A， MéNARD C， et al. Radiation abscopal antitumor effect is mediated through p53［J］. Cancer Res， 2003， 63（8）： 1990-1993. |
| 22 | JIANG H， YU K， CUI Y， et al. Combination of Immunotherapy and Radiotherapy for Recurrent Malignant Gliomas： Results From a Prospective Study［J］. Front Immunol， 2021， 12： 632547. doi:10.3389/fimmu.2021.632547 |
| 23 | SHAVERDIAN N， LISBERG A E， BORNAZYAN K， et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer： a secondary analysis of the KEYNOTE-001 phase 1 trial［J］. Lancet Oncol， 2017， 18（7）： 895-903. doi:10.1016/s1470-2045(17)30380-7 |
/
| 〈 |
|
〉 |